Macrophage-specific PHGDH protects against MAFLD by suppressing TAK1

Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a progressive disease with only one approved treatment currently available. Hepatic phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine biosynthesis pathway, regulates MAFLD development. However, the...

Full description

Bibliographic Details

Published in:	Cell Reports
Main Authors:	Penghui Hu, Xiao Shan, Hongyuan Dong, Sujun Yu, Baochen Wang, Hui Xiong, Zemin Ji, Weijia Jing, Yan Cui, Zihan Li, Yanzhao Zhou, Zhe Wang, Jinrong Wang, Jiuzhou Tang, Ting Wang, Keliang Xie, Qiujing Yu
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Subjects:	CP: Metabolism CP: Immunology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124725001974